Stocktoria
10x Genomics, Inc. TXG
Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2019-09-12
10x Genomics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% |
| Operating margin | -9.5% | -31.9% | -42.9% | -32.5% | -10.7% |
| Net margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% |
| FCF margin | 20.2% | -0.9% | -10.3% | -32.0% | -25.0% |
| Return on assets | -4.2% | -19.9% | -26.4% | -16.1% | -5.7% |
| Return on equity | -5.5% | -25.7% | -34.4% | -20.6% | -7.1% |
| Current ratio | 4.46 | 4.97 | 4.69 | 4.85 | 6.77 |
| Revenue growth | 5.2% | -1.3% | 19.8% | 5.3% | 64.1% |
Source: SEC EDGAR filings · CIK 0001770787 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.